Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00437021 · ClinicalTrials.gov registry record · Phase 1
MVA Post-Event: Administration Timing and Boost Study
A Phase 1 study of Smallpox, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 226
- Enrollment target
- 7
- Study locations
NCT00437021 is a Phase 1 study of Smallpox that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 226 participants, below the 131,019-participant average among 7 other Smallpox trials with a reported enrollment target (100% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT00437021, a Phase 1 study of Smallpox, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 226 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate an investigational smallpox vaccine, called IMVAMUNE®, with respect to safety and immune (body's defense system) response. Participants will include healthy adults, age 18 or older born after 1971, who have not had smallpox vaccine before. Participants were originally assigned to 1 of 5 groups. In July 2007, a hold was placed on the Dryvax® groups and the study was modified. Participants, will be assigned by chance to one of 3 groups to be vaccinated twice with IMVAMUNE® vaccine or placebo (inactive substance) in Groups A and B, or to receive a single vaccination with IMVAMUNE® or placebo in Group F. Participants will complete a memory aid (diary) for 15 days following vaccination. Blood samples will be collected. Participants may participate for up to 425 days.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Live vaccinia virus vaccine
- BIOLOGICAL MVA Smallpox Vaccine
Study Locations (7)
Iowa
- University of Iowa - Vaccine Research and Education Unit - Iowa City
Maryland
- University of Maryland, School of Medicine, Center for Vaccine Development and Global Health - Baltimore
Missouri
- Saint Louis University Center for Vaccine Development - St Louis
New York
- University of Rochester Medical Center - Strong Memorial Hospital - Infectious Diseases - Rochester
North Carolina
- Duke Translational Medicine Institute - Clinical Vaccine Unit - Durham
Ohio
- Case Western Reserve University - John T. Carey Special Immunology Unit - Cleveland
Texas
- University of Texas Medical Branch - Pediatrics - Infectious Diseases and Immunology - Galveston - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2007-04-16 |
| Est. Completion | 2009-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00437021
The ClinicalTrials.gov registry entry for NCT00437021 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131,019-participant average among 7 other Smallpox trials with a reported enrollment target (100% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smallpox appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00437021 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Iowa, Maryland, Missouri.
Frequently Asked Questions
What is clinical trial NCT00437021 about?
NCT00437021 is a clinical study titled "MVA Post-Event: Administration Timing and Boost Study". The purpose of this study is to evaluate an investigational smallpox vaccine, called IMVAMUNE®, with respect to safety and immune (body's defense system) response. Participants will include healthy adults, age 18 or older born after 1971, who have not had smallpox vaccine before. Participants were o...
What is the current status of trial NCT00437021?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 226 participants. The study started on 2007-04-16. Estimated completion is 2009-04-21.
What conditions does trial NCT00437021 study?
This clinical trial studies the following conditions: Smallpox.
What interventions are being tested in trial NCT00437021?
The interventions under investigation include: Placebo (OTHER), Live vaccinia virus vaccine (BIOLOGICAL), MVA Smallpox Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00437021?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00437021 being conducted?
This trial has 7 study locations across Iowa, Maryland, Missouri, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smallpox
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
ACTIVE NOT RECRUITING · Phase 2
-
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
COMPLETED
-
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
COMPLETED
-
Safety Surveillance Study of ACAM2000® Vaccinia Vaccine
COMPLETED
-
Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally
COMPLETED · Phase 2
-
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.